Medical Information

The medication precautions for Crizotinib involve multiple aspects such as liver function monitoring, cardiovascular risk management, and medication for special populations, which must be strictly followed to ensure treatment safety and effectiveness.

1. Liver function monitoring

(1) Regular testing of ALT/AST/bilirubin is required before and during treatment. In case of liver toxicity (ALT/AST>5 x upper limit of normal or bilirubin>3 x upper limit of normal), dosage adjustment or discontinuation of medication is necessary.

(2) If drug-induced liver injury occurs, measures such as suspending medication, reducing dosage, or permanently stopping medication should be taken according to the severity.

2 Cardiovascular system risks

(1) Monitor QT interval prolongation. If QTc>500 milliseconds, discontinue treatment and reduce dosage after recovery; If accompanied by tip twisting, the medication needs to be permanently discontinued.

(2) In case of symptomatic bradycardia (heart rate<60 times/minute), the administration should be suspended, and the dose should be adjusted after the combined effects of drugs are investigated.

3 respiratory system adverse reactions

(1) The incidence of interstitial lung disease/pneumonia is about 4%, and medication should be stopped immediately and evaluated when new cough, dyspnea, or fever occurs.

(2) After diagnosis of treatment-related pulmonary toxicity, crizotinib should be permanently discontinued.

4. Medication for special populations

(1) Women of childbearing age should take effective contraceptive measures during treatment and for at least 3 months after discontinuing medication, as animal experiments have shown embryotoxicity.

(2) Breastfeeding is prohibited during lactation, and breastfeeding is not allowed for at least 7 days after the last administration.

5 Dose Adjustment Standards

(1) If the missed dose is less than 6 hours before the next medication, it should not be taken again, and no additional dose should be given after vomiting.

(2) The first dose reduction is usually adjusted to 200mg bid, and the second dose reduction is 250mg qd. If it is still intolerable, the medication will be discontinued.